Zhitong Finance App News, Fu Hong Han Lin (02696.HK) announced that recently, the company's self-developed HLX3902 injection (steap1xCD3xCD28 triple-specific antibody) (HLX3902) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors was completed in China (excluding Hong Kong, Macao and Taiwan regions of China, same below). The company plans to conduct further relevant clinical trials in Australia when conditions are met.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.